Bmi-1 is induced by the Epstein-Barr virus oncogene LMP1 and regulates the expression of viral target genes in Hodgkin lymphoma cells

Blood

Volumn 109, Issue 6, 2007, Pages 2597-2603

  Dutton, Amanda ^a   Woodman, Ciaran B ^a   Chukwuma, Marilyn B ^a   Last, James I K ^a   Wei, Wenbin ^a   Vockerodt, Martina ^a   Baumforth, Karl R N ^a   Flavell, Joanne R ^a   Rowe, Martin ^a   Taylor, A Malcolm R ^a   Young, Lawrence S ^a   Murray, Paul G ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EMBRYONIC ECTODERM DEVELOPMENT PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LATENT MEMBRANE PROTEIN 1; PROTEIN BMI 1; UNCLASSIFIED DRUG;

ARTICLE; ATAXIA TELANGIECTASIA; CELL SURVIVAL; CONTROLLED STUDY; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENE MUTATION; HODGKIN DISEASE; HUMAN; HUMAN CELL; LYMPHOMA CELL; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; VIRUS ONCOGENE;

EID: 33947262695     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-05-020545     Document Type: Article

References (44)

1. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
2. Murray PG, Young LS, Rowe M, Crocker J. Immunohistochemical demonstration of the Epstein-Barr virus-encoded latent membrane protein in paraffin sections of Hodgkin's disease. J Pathol. 1992;166:1-5.
3. Bargou RC, Emmerich F, Krappmann K, et al. Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumour cells. J Clin Invest. 1997;100:2961-2969.
4. Huen DS, Henderson SH, Croom-Carter D, Rowe M. The Epstein-Barr virus latent membrane protein (LMP1) mediates activation of NF-κB and cell surface phenotype via two effector regions in its carboxyl-terminal cytoplasmic domain. Oncogene. 1995;10:549-560.
5. Simon J. Locking in stable states of gene expression: transcriptional control during Drosophila development. Curr Opin Cell Biol. 1995;7:376-385.
6. Jacobs JJL, Kieboom K, Marino S, De Pinho RA, van Lohuizen M. The oncogene and polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature. 1999;397:164-168.
7. Satijn DP, Otte AP. Polycomb group protein complexes: do different complexes regulate distinct target genes? Biochem. Biophys. Acta. 1999;1447:1-16.
8. Swalt RGAB, van der Vlag J, Gunster MJ, et al. Characterisation of interactions between the mammalian polycomb-group proteins EZH21/EZH2 and EED suggests the existence of different mammalian polycomb-group protein complexes. Mol Cell Biol. 1998;18:3586-3595.
9. Satijn DP, Hamer KM, den Blaauwen J, Otte AP. The polycomb group protein EED interacts with YY1, and both proteins induce neural tissue in Xenopus embryos. Mol Cell Biol. 2001;21:1360-1369.
10. Gunster MJ, Satijn DP, Hamer KM, et al. Identification and characterisation of interactions between the vertebrate polycomb group protein BMI1 and human homologs of polyhomeotic. Mol Cell Biol. 1997;17:2326-2335.
11. Shao Z, Raible F, Mollaaghababa R, et al. Stabilisation of chromatin structure by PRC1, a polycomb complex. Cell. 1999;98:37-46.
12. Alkema MJ, Jacobs H, van Lohuizen M, Berns A. Perturbations of B and T cell development and predisposition to lymphomagenesis in EuBMI1 transgenic mice require the BMI-1 RING finger. Oncogene. 1997;15:899-910.
13. van Lohuizen M, Verbeek S, Scheijen B, Wientjen E, van der Gulden H, Berns A. Identification of cooperating oncogenes in Eu-myc transgenic mice by provirus tagging. Cell. 1991;65:737-752.
14. Haupt Y, Alexander WS, Barri G, Klinken SP, Adams JM. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in Eu-myc transgenic mice. Cell. 1991;65:753-763.
15. Haupt Y, Bath ML, Harris AW, Adams JM. Bmi-1 transgene induces lymphomas and collaborates with myc in tumorigenesis. Oncogene. 1993;8:3161-3164
16. Bea S, Tort F, Pinyol M, et al. BMI-1 gene amplification and overexpression in haematological malignancies occur mainly in mantle cell lymphomas. Cancer Res. 2001;61:2409-2412.
17. Kim JH, Yoon SY, Kim CN, et al. The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett. 2004;203:217-224.
18. Vonlanthen S, Heighway J, Altermatt HJ, et al. The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer. 2001;84:1372-1376.
19. Raaphorst FM, van Kemenade FJ, Blokzijl T, et al. Polycomb-group genes in Reed-Sternberg cells of Hodgkin's disease. Am J Pathol. 2000;157: 709-715.
20. Dukers DF, van Galen JC, Giroth C, et al. Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma derived cell lines. Am J Pathol. 2004;164:873-881.
21. Sanchez-Beato M, Sanchez E, Garcia JF, et al. Abnormal PcG protein expression in Hodgkin's lymphoma: relation with E2F6 and NF-κB transcription factors. J Pathol. 2004;204:528-537.
22. Schaadt M, Diehl V, Stein H, Fonatsch C, Kirchner HH. Two neoplastic cell lines with unique features derived from Hodgkin's disease. Int J Cancer. 1980;26:723-731.
23. Baumforth KRN, Flavell JR, Reynolds GM, et al. Induction of autotaxin by the Epstein-Barr virus promotes the growth and survival of Hodgkin lymphoma cells. Blood. 2005;15:2138-2146.
24. Murray PG, Swinnen LJ, Constandinou CM, et al. BCL-2 but not its Epstein-Barr virus-encoded homologue, BHRF1, is commonly expressed in posttransplantation lymphoproliferative disorders. Blood. 1996;15:87:706-711.
25. Schakowski F, Buttgereit P, Mazur M, et al. Novel non-viral method for transfection of primary leukemia cells and cell lines. Genet Vaccines Ther. 2004;12;2:1-11.
26. Starczynski J, Simmons W, Flavell J, et al. Variations in ATM protein expression during normal lymphoid differentiation and among B-cell-derived neoplasias. Am J Pathol. 2003;163:423-432.
27. Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U. Control of IκBα proteolysis by site-specific, signal-induced phosphorylation. Science. 1995;267:1485-1488.
28. Cochet O, Frelin C, Peyron JF, Imbert V. Constitutive activation of STAT proteins in the HDLM-2 and L540 Hodgkin lymphoma-derived cell lines supports cell survival. Cell Signal. 2006;18:449-455.
29. Teofili L, Di Febo AL, Pierconti F, et al. Expression of the c-met proto-oncogene and its ligand, hepatocyte growth factor, in Hodgkin disease. Blood. 2001;15;1063-1069.
30. Garcia JF, Camacho FI, Morente M, et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood. 2003;15:681-689.
31. Zhang L, Hong K, Zhang J, et al. Multiple signal transducers and activators of transcription are induced by EBV LMP-1.Virology. 2004;323:141-152.
32. Horikawa T, Sheen TS, Takeshita H, Sato H, Furukawa M, Yoshizaki T. Induction of c-Met protooncogene by Epstein-Barr virus latent membrane protein-1 and the correlation with cervical lymph node metastasis of nasopharyngeal carcinoma. Am J Pathol. 2001;159:27-33.
33. Najjar I, Baran-Marszak F, Le Clorennec C, et al. Latent membrane protein 1 regulates STAT1 through NF-κB-dependent interferon secretion in Epstein-Barr virus-immortalized B cells. J Virol. 2005;79:4936-4943.
34. Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B, Scheidereit C. Molecular mechanisms of constitutive NF-κB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene. 1999;18:943-953.
35. Jungnickel B, Staratschek-Jox A, Brauninger A, et al. Clonal deleterious mutations in the IκBκ gene in the malignant cells in Hodgkin's lymphoma. J Exp Med. 2000;191:395-402.
36. Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene. 1999;18:6938-6947.
37. Hinz M, Lemke P, Anagnostopoulos I, et al. Nuclear factor κB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med. 2002;196:605-617.
38. Bargou RC, Leng C, Krappmann D, et al. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood. 1996;87:4340-4347.
39. Liu L, Andrews LG, Tollefsbol TO. Loss of the human polycomb group protein BMI1 promotes cancer-specific cell death. Oncogene. 2006;25:4370-4375.
40. Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K. Genome-wide mapping of polycomb target genes unravels their roles in cell fate transitions. Genes Dev. 2006;20:1123-1136.
41. Schwering I, Brauninger A, Klein U, et al. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2003;101:1505-1512.
42. Tjin Ep, Groen RW, Vogelzang I, et al. Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. Blood. 2006;107:760-768.
43. Pedersen PL, Mathupala S, Rempel A, Geschwind JF, Ko YH. Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim Biophys Acta. 2002;10:14-20.
44. Cao R, Tsukada Y, Zhang Y. Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. Mol Cell. 2005;22:845-54